stockrow
Friday 6 November 2026
Export IRON’s income statement to Excel — free account
Disc Medicine, Inc.
IRON Healthcare Biotechnology
- EPS
- +2.53%
- Free cash flow
- +7.83%
- Total debt
- +106.5%
Quarter to June 2026, against a year earlier
78.00
0.47
−0.60%
Follow IRON
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 33 | 33 | 169 | +127.6% | |
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | — | — | (41) | (36) | (47) | (76) | (109) | (212) | (246) | +39.0% | ||||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | 0 | (41) | (36) | (47) | (76) | (109) | (212) | (246) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | (27.02) | (40.97) | (45.05) | (3.42) | (3.96) | (6.01) | (6.58) | (26.0%) | ||||||
| Cash flow | — | — | — | — | (21.64) | (31.36) | (40.67) | (3.29) | (3.40) | (5.11) | (5.11) | (25.1%) | ||||||
| Capex | — | — | — | — | (0.01) | (0.08) | (0.15) | 0.00 | (0.02) | (0.03) | 0.00 | +12.6% | ||||||
| Free cash flow | — | — | — | — | (21.65) | (31.44) | (40.81) | (3.30) | (3.42) | (5.14) | (5.11) | (25.0%) | ||||||
| Book value | — | — | — | — | (14.46) | (73.12) | 169.97 | 15.47 | 16.07 | 20.96 | 16.65 | n/m | ||||||
| Shares, m | — | — | — | — | 2 | 1 | 1 | 22 | 28 | 35 | 37 | +87.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (33) | (28) | (42) | (73) | (94) | (180) | (198) | +40.7% | |||||
| Capex | — | — | — | — | 0 | 0 | 0 | 0 | (1) | (1) | (1) | +111.6% | ||||||
| Free cash flow | — | — | — | — | (33) | (28) | (42) | (74) | (94) | (181) | (198) | +40.8% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | (20) | 77 | 176 | 344 | 470 | 767 | 702 | n/m | |||||
| Net debt | — | — | — | — | 5 | (88) | (195) | (360) | (462) | (762) | (658) | n/m | ||||||
| Shareholders’ equity | — | — | — | — | (22) | (64) | 177 | 345 | 444 | 740 | 644 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (490.89) | (71.42) | (32.01) | (26.90) | (25.29) | (32.55) | (35.12) | (32.6) pt | |||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | 186.80 | 83.59 | (83.32) | (29.30) | (27.73) | (35.86) | (39.08) | (222.7) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 33 | 46 | 74 | 84 | 155 | — | +47.2% | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Disc Medicine, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics, Inc. | $3.7B | — (loss-making) | — (loss-making) | −95.44% (below 0%: shrinking) | n/m | +2.13% (above 0%: growing) | 100.00% | (25,949.71%) | Compare |
| ACAD ACADIA Pharmaceuticals Inc. | $3.7B | 10.0× | 33.4× | +22.85% (above 0%: growing) | −27.91% (below 0%: shrinking) | +141.15% (above 0%: growing) | 89.75% | 20.95% | Compare |
| XENE Xenon Pharmaceuticals Inc. | $3.7B | — (loss-making) | — (loss-making) | +100.70% (above 0%: growing) | n/m | −48.57% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| TNGX Tango Therapeutics, Inc. | $3.5B | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −4.58% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IOVA Iovance Biotherapeutics, Inc. | $3.5B | — (loss-making) | — (loss-making) | +80.07% (above 0%: growing) | n/m | +89.72% (above 0%: growing) | 0.00% | (19.73%) | Compare |
| IRON Disc Medicine, Inc. | $3.5B | — (loss-making) | — | — | n/m | +7.83% (above 0%: growing) | 0.00% | 0.00% | |
| PBLS Parabilis Medicines, Inc. | $3.4B | — (loss-making) | — | — | n/m | — | 100.00% | (34,382.43%) | Compare |
| VKTX Viking Therapeutics, Inc. | $3.3B | — (loss-making) | — | — | n/m | −47.01% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| DYN Dyne Therapeutics, Inc. | $3.2B | — (loss-making) | — | — | n/m | −39.08% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $3.5B | — | — | +22.85% | — | −4.58% | 44.88% | 0.00% |
Pay and ownership Proxy statement filed 28 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 9.99m | 13.48m | 257.82 |
| 2024 | 9.07m | 8.67m | 205.84 |
| 2023 | 909.10k | 5.23m | 187.53 |
| 2022 | 1.83m | 1.18m | 64.58 |
Ownership
Directors and executive officers, together
3.76%
FMR LLC
13.87%
AI DMI LLC
7.86%
RA Capital Management, L.P.
5.84%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement